MabCure Welcomes Dr. Charles T. Tackney as New Chief Scientific Officer
06 Diciembre 2010 - 8:34AM
Business Wire
Biotechnology company MabCure, Inc. (OTCBB: MBCI) today
announced that it has appointed Dr. Charles T. Tackney as its new
Chief Scientific Officer.
Dr. Tackney is a scientific and business leader with diverse
experience in clinical medicine and new technology development,
spanning the areas of molecular biology, biotechnology and
diagnostics. Since 2009, Dr. Tackney has served as the Chief
Scientific Officer at NeuroMark Genomics, Inc. Prior to that, he
worked in various positions for the Ortho Clinical Diagnostics unit
of Johnson & Johnson, including, Director of Diagnostic
Biomarker Evaluation Group, Scientific Director of Advanced
Research & Technology Assessment World Wide, and Director of
Prion Research Group. Earlier in his career, Dr. Tackney served as
the Director of the Department of Molecular Biology at ImClone
Systems Inc., now a wholly-owned subsidiary of Eli Lilly.
Dr. Tackney earned his Ph.D. in molecular genetics from the City
University of New York and was awarded a postdoctoral research
fellowship from the Damon Runyon Foundation at Columbia University
College of Physicians and Surgeons.
“We are pleased to have Dr. Tackney join us as our new Chief
Scientist,” said Dr. Amnon Gonenne, MabCure’s President and CEO.
“His vast experience in developing antibodies, diagnostics and
therapeutics will undoubtedly contribute to the future of MabCure.
With his leadership and expertise, we anticipate the company will
accelerate towards achieving its milestones and the shared goals of
our shareholders, employees, and patients alike.”
About MabCure
MabCure is a U.S. biotechnology company whose mission is to
change the perception of cancer as being a largely incurable
disease. MabCure owns proprietary technology for the creation of
unique and highly specific monoclonal antibodies (MAbs), which the
company plans to develop as diagnostic tools, imaging agents and
therapeutic drugs to treat lethal cancers. The company’s initial
focus is on the development of novel diagnostic tests for the early
detection of ovarian, prostate, and colorectal cancers, each with
multi-billion dollar global market potential. MabCure is also
currently exploring the potential of its anti-melanoma antibodies
for the development of imaging and therapeutic agents. For
more information about MabCure and to sign up for e-mail updates,
visit www.mabcure.com.
This news release contains “forward-looking statements.”
Statements in this news release which are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the change of business focus of the
management of the Company and the inability of the Company to
pursue its current objectives. These forward-looking statements are
made as of the date of this news release and the Company assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements.
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
